Comparing three chemotherapy regimens for newly diagnosed blood cancer
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests three different chemotherapy regimens for adults 15–65 years old with newly diagnosed acute myeloid leukemia (AML)—a serious blood cancer. The goal is to see which treatment approach works best for patients with intermediate or high-risk disease who are fit enough for intensive chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have newly diagnosed acute myeloid leukemia (AML), confirmed by blood/bone marrow tests
- Your AML is classified as intermediate-risk or high-risk based on genetic testing
- You are between 15 and 65 years old
- Your liver and kidneys function well enough (measured by blood tests)
- Your heart is healthy with normal pumping strength
- You are physically able to tolerate intensive chemotherapy (good overall health)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests three different chemotherapy regimens (LDA, LHAA, and DA) in adults aged 18–65 with newly diagnosed acute myeloid leukemia (AML, a blood cancer). The goal is to find which approach works best and is safest for patients fit enough for intensive treatment.
This trial tests a new combination of drugs (lisafotoclax, decitabine, and homoharringtonine) for people with AML who have already tried venetoclax and azacitidine and it didn’t work. The goal is to find a treatment that might work when the first therapy fails.
This trial tests if taking a combination of two medicines, Lisaftoclax and Azacitidine, after a stem cell transplant can help prevent acute myeloid leukemia (AML) from coming back in patients who have a high risk of relapse.
This trial compares a new combination of drugs (venetoclax, azacitidine, and liposomal mitoxantrone) against a standard chemotherapy regimen (idarubicin and cytarabine) for people with newly diagnosed acute myeloid leukemia (AML). It tests whether the new combination works better and is safe.
This trial tests whether giving chemotherapy drugs on a 2-week schedule versus a 3-week schedule works better for newly diagnosed acute myeloid leukemia (a blood cancer). The goal is to find which schedule helps more patients go into remission (where cancer cells disappear).
This trial compares four different combinations of targeted therapy and chemotherapy for people with newly diagnosed AML who cannot have standard intensive chemo. The goal is to see which combination works best safely.
Hear when a new Acute Myeloid Leukemia (AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.